Literature DB >> 27793455

Effects of long-acting GnRH antagonist, degarelix acetate, on plasma insulin-like peptide 3, testosterone and luteinizing hormone concentrations, and scrotal circumference in male goats.

M A Hannan1, N Kawate2, Y Fukami1, W W P N Weerakoon1, E E Büllesbach3, T Inaba1, H Tamada1.   

Abstract

We recently reported that plasma insulin-like peptide 3 (INSL3) concentrations increased soon after endogenous and exogenous stimulations of LH in male goats and bulls. However, the effects of LH suppression on INSL3 secretion are unknown in domestic animals. Here, we examined the effects of a long-acting GnRH antagonist (degarelix acetate; 4 mg/kg) on the secretions of plasma INSL3 and testosterone in two phases, an immediate and a long-term phase in male goats (n = 6; aged, 13-16 months). During the immediate phase, blood was taken at 15-minute intervals for 8 hours on Days -5, 0, and 3. The GnRH antagonist was administered after 2-hour sampling of Day 0. Moreover, a daily blood sample was taken from Day 0 to Day 7, followed by twice a week until 9 weeks and finally at week 10. The scrotal circumference was recorded before treatment and continued biweekly until week 10. Concentrations of LH, INSL3, and testosterone in plasma were determined by EIA and the pulsatile nature of secretion analyzed using pulse XP software. The mean concentrations, pulse frequency (per hour), and pulse amplitude (peak-nadir) of plasma LH and testosterone reduced from pretreatment to posttreatment Day 0 and Day 3 (P < 0.05). A decline in mean concentrations, pulse frequency, and pulse amplitude of INSL3 was exhibited on posttreatment Day 3 compared with pretreatment (P < 0.01). During long-term sampling, a decline (P < 0.01) in plasma testosterone and INSL3 concentrations was observed 1 day after treatment and remained lower until 8.5 weeks after treatment, and thereafter returned to pretreatment levels. A reduction in scrotal circumference was recorded 4 weeks after treatment and remained lower until 10 weeks after treatment (P < 0.05). In conclusion, the acute regulation of INSL3 by LH was confirmed by reduction of plasma INSL3 levels within 3 days after GnRH antagonist treatment in male goats. Although the onset of suppression of testosterone was more rapid than that of INSL3, the low levels persisted for 8.5 weeks for both hormones, and subsequently the concentrations returned to pretreatment levels. A significant reduction in testicular size was also observed. The quick, long-lasting, and transient suppression of testosterone and INSL3 after a single injection implies a potential application of this antagonist in reversible long-term chemical castration in male goats.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GnRH antagonist; INSL3; LH; Male goat; Scrotal circumference; Testosterone

Mesh:

Substances:

Year:  2016        PMID: 27793455     DOI: 10.1016/j.theriogenology.2016.09.032

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  3 in total

1.  The GnRH Antagonist Degarelix Suppresses Gonadotropin Secretion and Pituitary Sensitivity in Midgestation Sheep Fetuses.

Authors:  Rebecka Amodei; Sonnet S Jonker; William Whitler; Charles T Estill; Charles E Roselli
Journal:  Endocrinology       Date:  2022-02-01       Impact factor: 5.051

2.  Relationships of plasma insulin-like peptide 3, testosterone, inhibin, and insulin-like growth factor-I concentrations with scrotal circumference and testicular weight in Japanese Black beef bull calves.

Authors:  Mitsuhiro Sakase; Keita Kitagawa; Masahiko Kibushi; Noritoshi Kawate; W W P N Weerakoon; M A Hannan; Namiko Kohama; Hiromichi Tamada
Journal:  J Reprod Dev       Date:  2018-07-06       Impact factor: 2.214

3.  Inhibitory effects of long-term repeated treatments of a sustainable GnRH antagonist, degarelix acetate, on caprine testicular functions.

Authors:  Noritoshi Kawate; Ryota Kanuki; M A Hannan; Weerakoon W P N Weerakoon
Journal:  J Reprod Dev       Date:  2020-08-21       Impact factor: 2.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.